1. Beyond the GAIN Act: Some Thoughts on Expediting Antibacterial Development to Address the Problem of Antimicrobial Resistance

   • Mark J. Goldberger

   Current Opinion 24 February 2016 Pages: 71 - 78

2. Structured Qualitative Benefit-Risk Assessment to Inform Go/No-Go Decisions for Phase III Testing of Pharmaceutical Products

   • Anne Wolka
   • Christine Radawski
   • Rebecca Noel

   Leading Article 13 January 2016 Pages: 79 - 85

3. Pharmacovigilance in Nigeria: An Overview

   • Abimbola Olowofela
   • Annie Fourrier-Réglat
   • Ambrose O. Isah

   Leading Article 19 January 2016 Pages: 87 - 94

   

4. Variation in Liver Biochemistries in Patients with Decompensated Cirrhosis: Implications for Assessing Drug-Induced Liver Injury in Clinical Trials

   • Marzena Jurek
   • Masoud Mokhtarani
   • Bruce F. Scharschmidt

   Short Communication 11 January 2016 Pages: 95 - 101

   

5. A Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries

   • Christopher D. Breder

   Short Communication 02 February 2016 Pages: 103 - 108

   

6. Trends in the Location of Phase 3 Clinical Trials Between 2008 and 2012: A Retrospective Review Utilizing ClinicalTrials.gov

   • Harold E. Glass
   • Lucas M. Glass
   • Ananya Jain

   Original Research Article 29 January 2016 Pages: 109 - 115

   

7. Forum

   Update 22 February 2016 Pages: 117 - 128

8. Major Pharmaceutical Conferences and Courses

   Update 17 February 2016 Pages: 129 - 132